The distribution of cyclosporin A (CsA) 
Despite intensive treatment with corticosteroids and/or cytotoxic drugs the visual outcome in chronic endogenous uveitis and more so in uveitis accompanying Behcet's disease is extremely poor.' Because of the relentless loss of vision leading to blindness in most of these cases many forms of treatment have been tried. None, however, was satisfactory. ' With the emergence of the new immunomodulating drug cyclosporin A (Sandimmun) as an effective treatment in kidney transplantation2 its effects on experimental autoimmune uveitis (EAU) were studied.3 Owing to the benefits of CsA in the experimental animal clinical studies have been initiated. In most ofthem the drug was found to be effective in abating the acute intraocular inflammation and preserving vision, even in uveitides refractive to conventional therapy." However, the nephrotoxic risk of its prolonged use has inhibited its systemic use for the routine treatment of uveitis." To reduce the risk of toxicity of systemic treatment the possibility of using local applications has been investigated.
We report here our observations on the penetration of cyclosporin A into the human eye after local ocular application or systemic ingestion of the drug.
Materials and methods

PATIENTS
Twelve patients (nine males and three females) with ocular Behcet's disease (groups 1 and 2), three patients with neuro-Behcet's disease (two males and one female, group 3), and six male patients undergoing routine cataract extraction without any ocular inflammation (group 4) were included in this study. In the ocular Behqet's disease groups six patients suffered from severe panuveitis at least in one eye (group 1) and six patients had signs of mild anterior uveitis with posterior involvement mainly in the peripheral fundus in one or two eyes (group 2).
In Detectable levels of the drug were also observed in the saliva of these patients. However, no CsA was found in the aqueous humour in these cases (Fig 1) . The aqueous humours did not show any detectable levels of CsA when the tests were repeated by HPLC. After local application ofthe 2% CsA eye drops in this group of patients, all fluid samples were devoid ofany measurable CsA (Fig 1) .
Patients with mild posterior uveitis accompanying the manifestations of ocular Behcet's Oral -5mg/kg E Eye drops (2%) disease had no detectable levels of CsA in the aqueous humour after oral or local treatment (Fig 2) . Low levels of CsA were detected in the tears and saliva of those patients treated systemically with 5 mg/kg/day of cyclosporin A (Fig 2) .
In the group of patients with ocular Behqet's disease and severe panuveitis, 'treatment' with local eye drops did not induce any intraocular penetration of CsA. However, after systemic treatment high levels of CsA were found in the aqueous humour and in the vitreous (Fig 3) . Systemic treatment resulted also in measurable levels of the drug in the saliva and tears of these patients. Measurable levels of CsA in tears were observed only in one of the patients in this group treated with eye drops (Fig 3) .
The distribution of CsA in patients with
Behqet's disease and central nervous system involvement was similar to that observed in the other groups after systemic treatment with the drug. In the cerebrospinal fluid, however, no measurable levels of CsA were observed (Fig 4) .
Discussion
The data obtained in this study demonstrate that in the human eye topical instillation of2% CsA in olive oil does not result in any measurable levels of the drug in the aqueous humour or the vitreous even in eyes with severe panuveitis. These results correlate well with our previous observations in the rabbit (BenEzra and Maftzir, to be published) and rat eyes (BenEzra and Maftzir, to be published) using radioactive and non-ratioactive CsA in inflamed or non-inflamed eyes. BenEzra, Maftzir, de Courten, Timonen
The findings of CsA in the aqueous humour of rabbit eyes following corneal grafting as reported by others" may be explained by the possible 'easier' penetration of the drug via the wound between the host and graft. However, the relatively high levels of CsA in the contralateral eye of these rabbits as observed by these workers are surprising. Although a 'recirculation effect' has been suggested as the explanation of similar findings," 12 in our opinion the strong and tight blood-retinal barrier in the intact eye prevents any possible intraocular penetration via the systemic recirculation. Therefore studies demonstrating intraocular penetration of CsA in untreated healthy contralateral eyes after local application of oil solution (or systemic administration) of CsA should be carefully re-evaluated. Species specific differences regarding the metabolism of CsA have been observed.'3 However, from our studies it appears that the ocular distribution ofthe drug in the rabbit, the rat, and the human eye is similar.
After oral ingestion of the drug high blood levels have been found in all patients. Significant detectable levels of CsA were also observed in saliva and tears. These results may reflect the high differential uptake of CsA in these glands. Indeed, a high specific uptake of CsA in the salivary glands of experimental animals has been demonstrated.'4 Our study further shows that specific concentration of CsA is probably also taking place in the human lacrimal gland. These findings may be helpful when considering the possible use of CsA in non-infectious inflammatory diseases affecting the salivary and/or lacrimal glands.
Regarding the intraocular penetration of CsA, however, there is a definite and clear differentiation between the findings observed in the noninflamed or mildly inflamed eyes on the one hand, and the eyes with severe uveitis on the other. Obviously, in the latter, the breakdown of the blood-retinal barrier and the leaky nature of the intraocular blood vessels allow penetration of the lipophilic molecule of CsA into the aqueous humour and vitreous. These results are in line with the observations of measurable levels of CsA in the aqueous humour of a few patients with uveitis'5 and Behqet's disease. '6 In earlier studies we have observed detectable levels of CsA in the aqueous humour after local application of the drug in rabbit eyes with severe intraocular inflammation (BenEzra and Maftzir, to be published). High levels of CsA in the aqueous humour have also been observed in the rat eye when extensive damage of the cornea was induced by topical application of absolute alcohol eye drops (BenEzra and Maftzir, to be published). In the human eye, however, as shown in this study, no detectable levels of CsA were found either in the aqueous humour or in the vitreous after local application of 2% CsA in olive oil even in eyes with severe panuveitis. These differences between the inflamed rabbit eye and the human eye with uveitis may be due to the fact that the corneas of the inflamed rabbit eyes were oedematous, while in the patients' eyes with uveitis the corneas were not affected.
Our findings clearly demonstrate that detectable levels of cyclosporin A in the human eye are observed only in eyes with severe uveitis after systemic ingestion of the drug. Thus breakdown of the blood-retinal barrier is necessary to allow intraocular penetration of CsA. After topical application of2% CsA oil solution the drug is not observed within the human eye, even in eyes with severe panuveitis. 
